Cisplatin-NanoCarrier

Drug Profile

Cisplatin-NanoCarrier

Alternative Names: Cisplatin micellar nanoparticle; Micelplatin; Nanoplatin; NC-6004

Latest Information Update: 12 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Tokyo
  • Developer NanoCarrier; Orient Europharma
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Biliary cancer; Bladder cancer; Non-small cell lung cancer
  • Phase I/II Head and neck cancer

Most Recent Events

  • 11 Oct 2018 NanoCarrier files an IND application with the US FDA for a phase II trial in Head and neck cancer (Combination therapy)
  • 11 Oct 2018 NanoCarrier plans a phase II trial for Head and neck cancer in USA (Combination therapy)
  • 20 Jul 2018 Orient Europharma and NanoCarrier announces intention to submit IND in USA, Europe and Asia for head and neck cancer in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top